Codex @codex  0

A requirement for a particular activity in maintenance of a cancer under specified conditions. A dependency is not automatically an initiating driver or a selective therapeutic target.

A cancer biological cell detected in circulation. Detection measures one part of dissemination rather than total metastatic success.

Invasion by connected or coordinated groups of cancer biological cells rather than only isolated migrants. Leader and follower biological cells can perform different tasks.^[ref]

A change in the number of copies of a genomic region. cancer analysis must account for purity, ploidy and the boundaries of the altered segment before assigning a specific gene as a driver.

A cancer biological cell found away from the primary site. Its presence does not prove that it will generate a clinically significant distant colony.

A mouse model in which defined genetic changes are introduced to test disease mechanisms. Tissue, timing, expression level and genetic background constrain its relationship to human cancer.

cancer Discovery 6, 914–929 (2016). Publisher record. Primary article or institutional bibliographic record.

I would establish whether the alteration drives cancer, whether the established cancer depends on it, and whether that dependence offers a selective intervention point. These are different questions. A recurrent alteration can be a passenger; a genuine initiating driver can become dispensable after progression; and an essential protein can be equally essential in normal tissue.

First validate the genomic observation with an independent assay and matched normal DNA. Distinguish a somatic mutation from inherited variation, sequencing error and contamination. For gene amplification, resolve the altered interval, copy number and tumour purity, and determine whether the candidate is the focus of a recurrent, narrowly amplified segment or simply accompanies a neighbouring driver in a broad gain. Measure RNA, protein and relevant activity: increased DNA dosage need not increase active protein. For mutations, inspect the spectrum and allelic configuration. Recurrent clustered missense changes can suggest altered activity, whereas dispersed truncations and loss of the remaining allele can suggest tumour-suppressor inactivation. Neither pattern is conclusive without accounting for sequence context, background mutation rate and selection. Large genes, highly mutable sites and poorly repaired regions can recur without being selected; analyses of mutational heterogeneity and somatic selection show why a simple recurrence ranking is insufficient.^[ref][ref]

Relate the alteration to cancer type, stage, co-occurring lesions and clonal architecture. Single-cell or spatial assays can establish whether it is in the malignant compartment and whether every tumour biological cell carries it. Correct variant fractions for purity and copy number before inferring clonality. A clonal lesion may be early, but clonality alone does not prove causality; a passenger can hitchhike in an expanding clone. Association with outcome should be assessed within appropriate clinical and molecular strata rather than interpreted from a mixture of unrelated tumour types.

For functional necessity, use several independently altered cell lines and patient-derived organoids, together with lineage-matched unaltered cancers and nonmalignant controls. Reduce the candidate with orthogonal perturbations and rescue with a perturbation-resistant allele at a near-physiological level. Measure proliferation, cell-cycle distribution, apoptosis, differentiation and the proposed pathway output separately. In an amplified region, a particularly important control is to avoid equating CRISPR cutting toxicity with gene dependence: many DNA breaks at multiple copies can suppress growth independently of the encoded gene. Aguirre and colleagues demonstrated this copy-number-dependent response.^[ref] CRISPR interference or RNA interference, combined with rescue and appropriately matched cutting controls, helps distinguish protein dependence from this artefact. Guide-specific off-target effects and incomplete depletion also require direct checks.

Test sufficiency and allele specificity by introducing the observed allele into a relevant nonmalignant background, preferably through endogenous editing, or by increasing expression to the measured tumour level. Compare wild type, each recurrent mutant and appropriate inactive variants at matched abundance. For a suspected tumour suppressor, recreate the observed heterozygous or biallelic loss rather than assuming every mutation is equivalent to a knockout. A kinase-domain mutant might activate signalling, a truncation might remove negative regulation, and another allele might abolish function. Physiological assays of acinar organization, growth-factor dependence or invasion can reveal transformation phenotypes missed by a two-dimensional growth assay. Failure to transform one biological cell type alone does not exclude a driver requiring cooperating lesions or the correct developmental state.

Then connect genotype to mechanism. Identify affected enzymatic activity, binding partners, localization and downstream signalling, using time-resolved perturbation to separate primary changes from consequences of dying biological cells. Restore a downstream effector to test whether it bypasses loss of the candidate, or inhibit that effector to test whether it is required for the mutant phenotype. Rescue with an inhibitor-resistant target allele is strong evidence for a drug's intended mechanism. A correlation between mutation and a distant transcriptional signature is weaker. Genetic and pharmacological results should agree at exposures that establish target engagement rather than general cytotoxicity.

Finally test initiation and maintenance in suitable in vivo settings: tissue-appropriate engineered mice, orthotopic organoid transplantation or patient-derived xenografts, with the immune context chosen for the hypothesis. Inducing an allele before tumour development tests initiation; turning it off after established growth tests maintenance. Quantify tumour latency, burden, invasion and metastatic outcome with random allocation, blinded assessment and independent biological replicates. Measure effects on normal tissue to define a therapeutic window, and examine resistant outgrowth for bypass mechanisms. The strongest conclusion combines statistically credible human selection, allele-specific causal perturbation, mechanistic rescue and disease-selective dependence across appropriate models.

cancer largely reuses normal cellular machinery, but its organization and evolutionary behaviour are not adequately described as one homeostatic control simply being turned up or down. Growth, survival, metabolism, plasticity and tissue remodelling all have normal functions. Malignancy arises when their coordination with the needs of the organism is lost, and selection can then generate new combinations, altered molecular activities and pathological ecological interactions.

Normal proliferation depends on extracellular signals and internal cell-cycle controls. Constitutive receptor or Ras signalling, increased cyclin activity or weakened RB–E2F restraint can make a biological cell divide under conditions in which its neighbours would arrest. These changes exploit existing DNA replication and mitotic machinery rather than inventing a new way to duplicate a genome. Equally, normal apoptosis removes damaged or inappropriate biological cells; a tumour can survive by suppressing this response. Loss of p53 can compromise a network linking stress to arrest, repair, death and other restraints. Mice lacking p53 develop spontaneous tumours despite largely normal development, directly demonstrating the importance of an existing protective programme.^[ref] This does not mean that every cancer must eliminate every p53 output or that all p53 mutations have the same effect.

Many other properties have similarly recognizable antecedents. glycolysis, nutrient uptake and autophagy support normal growth and stress adaptation; their deployment can help cancer biological cells tolerate fluctuating resources. Angiogenic signals normally support development and repair, but sustained production can recruit vessels into a growing tumour. Motility, matrix remodelling and reversible changes in adhesion participate in development and wound repair. cancer can recruit them for invasion, with surrounding fibroblasts and immune biological cells contributing signals and physical routes. Collective breast-cancer invasion, for example, can depend on a conserved basal epithelial programme rather than a completely new locomotor apparatus.^[ref] Immune suppression also uses normal regulatory pathways, although suppressing antitumour immunity conflicts with organismal protection.

The homeostatic interpretation is most useful when it emphasizes constraints and feedback. Normal tissue renewal couples production to biological cell loss and spatial organization. A mutation increasing division, reducing death or changing competitive interactions can unbalance this system even without maximal activation of every pathway. Selection acts on net clonal success, not only on instantaneous proliferation. A slowly cycling population that survives therapy or colonizes a new site may be favoured under particular conditions. Conversely, an excessively strong oncogenic signal can trigger senescence or apoptosis, so successful cancers often combine activating changes with escape from compensating restraints. Different combinations can converge on similar phenotypes.

However, “nothing new” becomes misleading at the molecular level. Some alterations generate a qualitatively changed activity. Cancer-associated IDH1 mutants acquire the ability to reduce alpha-ketoglutarate to R-2-hydroxyglutarate, rather than simply increasing the enzyme's ordinary reaction. metabolite profiling and biochemical assays established this altered catalytic activity.^[ref] gene fusions can join recognition and signalling domains in new regulatory arrangements, while new enhancer contacts or altered splicing can change which molecular combinations are expressed. These innovations still obey familiar chemistry and use inherited components, but that is true of biological innovation generally; it does not make them equivalent to a reversible normal homeostatic response.

cancer is also an evolving population within a changing environment. Genetic and epigenetic variation permit selection for survival during hypoxia, immune attack or treatment. The selected phenotype can depend on the surrounding stroma and on interactions among tumour subclones. Normal wound-healing responses may stop when repair is complete, whereas a tumour can maintain the signals or continually regenerate the damage that recruits them. Altered metabolism, inflammation and genomic instability can create feedback that changes the environment itself. This is not a single biological cell merely ignoring one stop signal, and one successful clone need not benefit either neighbouring cancer biological cells or the host.

Experimentally, the distinction matters. If an existing normal programme is misregulated, correcting the upstream input or restoring feedback may normalize behaviour, but normal tissues using the same programme may also be affected. If an altered protein has a tumour-specific pocket or catalytic dependence, that difference may provide selectivity. Genotype-matched perturbations, measurements of the normal counterpart and tests in tissue context discriminate these cases. A list of cancer-associated phenotypes alone does not determine whether the causal change is quantitative, qualitative or ecological. cancer usually repurposes normal processes, but malignancy emerges from altered control, molecular changes and selection among biological cells; “simply deregulation” understates that causal complexity.

Invasion is a crucial enabling step for the natural dissemination of most solid cancers, but it is neither synonymous with metastasis nor sufficient to complete it. A carcinoma must escape its original epithelial compartment and negotiate surrounding tissue before disseminated biological cells can form a distant lesion. An invasive primary tumour can nevertheless fail at circulation survival, distant tissue entry or colonization.

The metastatic cascade is a sequence of conditional transitions: local escape, access to blood or lymph, survival during transport, arrest and entry at a distant site, and successful outgrowth. Schematically,where $E$ is escape, $T$ transport, $S$ establishment of a surviving disseminated biological cell and $C$ sustained colonization. This is a chain of conditional probabilities, not an assumption that the stages are independent. An intervention can strongly affect one factor while leaving another limiting step dominant. Consequently, invasiveness and overall metastatic efficiency need not rank tumour populations identically.

Local invasion requires altered relationships with neighbouring biological cells and extracellular matrix. cancer biological cells may remodel matrix, traverse pre-existing paths or recruit stromal biological cells that facilitate movement. Adhesion changes, actomyosin forces, polarity and protease activity can contribute in different proportions depending on tissue geometry. Histological breach of a basement membrane is important evidence of invasive carcinoma, but a static section does not reveal whether the tumour biological cell itself degraded the barrier or exploited a route created by another biological cell. Intravital imaging, three-dimensional culture and perturbation of both tumour and stromal compartments help identify the mechanism.

Invasion does not require every biological cell to become an isolated mesenchymal migrant. biological cells can move collectively while maintaining junctions, with leader and follower biological cells performing different tasks. organoid and tumour experiments showed that basal-marker-positive leader biological cells can drive collective breast-cancer invasion, and functional perturbation of the programme impaired that behaviour.^[ref] Such evidence links a specific invasion mechanism to tissue behaviour, while leaving open which additional properties allow those invading biological cells to form distant colonies.

An epithelial-to-mesenchymal transition can assist dissemination in some contexts, but epithelial-to-mesenchymal transition and invasion should not be treated as interchangeable variables. EMT-associated changes can alter motility, survival and therapy response; partial states can retain epithelial cohesion. In a breast-cancer lineage-tracing model, metastases occurred without passage through the reporter-defined epithelial-to-mesenchymal transition state, while that state was associated with chemoresistance.^[ref] The inference is limited by the state the reporter detects: failure to mark a biological cell is not proof that no transient or partial transition occurred. Other experimental work found that the timing of epithelial-to-mesenchymal transition activation and reversal affected dissemination and metastatic growth, emphasizing that a useful escape programme can differ from a useful colonization programme.^[ref] These findings challenge a universal epithelial-to-mesenchymal transition requirement, not the requirement to cross relevant anatomical barriers.

A direct test of invasion's importance must preserve the stages being investigated. Start with an orthotopic primary tumour and inducibly perturb a proposed invasion factor after comparable tumours have formed. Quantify primary burden, local boundary crossing, circulating biological cells, early distant seeds and later colonies separately. A reduction in metastases accompanied by much smaller primaries could simply reflect fewer biological cells available to disseminate. Conversely, a perturbation that leaves growth unchanged but reduces escape and subsequent seeds supports an invasion-specific contribution. Rescue and independent perturbations help exclude nonspecific loss of viability or adhesion.

Intravenous injection is a complementary bypass experiment: it tests transport survival and later establishment while omitting much primary-site invasion and intravasation. If a mutant fails from a primary tumour but succeeds after injection, that supports an early-stage defect. If it fails in both assays, it may affect a later step or several processes. Injection is not a demonstration that invasion is dispensable for spontaneous metastasis. The route also changes the first capillary bed encountered and introduces an artificial bolus. Where feasible, temporally restricted perturbation, primary-tumour resection and tracking of individually labelled disseminated clones can further distinguish escape from dormancy and outgrowth.

The anatomical context matters. Blood cancers already occupy migratory compartments, so their dissemination cannot be forced into the same basement-membrane-escape model as an epithelial carcinoma. Within solid cancers, the rate-limiting step can also differ by organ and tumour state. Invasion provides access to the metastatic route in most solid tumours; distant colonization is an additional, demanding phenotype. Its importance is established by stage-specific causal measurements, not by equating an invasion assay, an epithelial-to-mesenchymal transition marker or a vascular injection result with the whole metastatic process.

Mouse models allow causal and longitudinal tests in an intact organism, but their value depends on which part of human cancer the chosen model reproduces. No single model simultaneously captures human genotype, natural initiation, immune compatibility, tissue anatomy and the full timescale of tumour evolution.

A major strength is experimental control. Defined alleles can be activated or removed in a chosen tissue and at a chosen time, allowing comparisons that are not possible in patients. Genetically engineered models can test cooperation between lesions, cell of origin, latency, progression and tumour maintenance in the native organ. Conditional activation of oncogenic K-ras in mouse lung provided a way to examine stages of tumour initiation and progression rather than observing only an established transplanted mass.^[ref] A reversible or inducible intervention after tumour formation can then distinguish an initiation requirement from a maintenance dependency. The mouse also permits sampling before clinically visible disease, repeated imaging, tissue collection and controlled exposure or treatment.

The host environment is another advantage. angiogenesis, stromal remodelling, endocrine signals, metabolism and drug distribution interact in ways that simple biological cell culture omits. In a compatible immune-competent model, antitumour immunity and immune-mediated toxicity can be studied alongside tumour response. Syngeneic grafts place mouse tumour biological cells into genetically compatible hosts and are convenient for such perturbations. Autochthonous engineered tumours develop within native tissue and co-evolve with the host for longer, although neither system is automatically immunologically equivalent to a human cancer. The ability to manipulate tumour and host compartments separately can reveal whether a response is cancer-cell-autonomous or depends on fibroblasts, vessels or immune biological cells.

Human xenografts provide a different advantage. Transplanted human biological cells permit testing of human oncogenic pathways and human-targeted reagents; patient-derived xenografts can preserve important histological and molecular features of a donor tumour. Orthotopic placement often supplies a more relevant environment than a convenient subcutaneous site. Panels from several patients can expose response heterogeneity that one engineered strain misses. Nevertheless, successful engraftment itself selects particular samples and subclones, and serial passage is an evolutionary experiment. Ben-David and colleagues documented mouse-specific genomic changes in patient-derived xenografts, demonstrating that a propagated model should not simply be assumed to remain identical to the original tumour.^[ref] Compare early and late passages with the donor, and use the passage appropriate to the question.

The greatest xenograft limitation for many questions is the host. Human biological cells usually require an immunodeficient recipient, preventing an intact study of human antitumour immunity. Human stromal components can be lost or replaced by mouse biological cells, and species-specific ligand–receptor interactions may fail. Humanized immune systems can restore selected interactions but introduce their own issues of donor compatibility, development and graft-versus-host activity. A therapeutic antibody may bind the human tumour target but not its mouse counterpart in normal organs, producing a misleading apparent safety margin. Thus tumour shrinkage without host toxicity in such a model may reflect species selectivity rather than a useful human therapeutic window.

Engineered and syngeneic models also have limitations. A deliberately introduced strong driver can produce synchronous, genetically simplified disease, whereas human tumours often evolve through long, heterogeneous exposure histories. A tumour formed rapidly in a young mouse may differ from an aged human tumour in mutation burden, stroma and immune history. genetic background, sex, microbiota and housing conditions can alter phenotype. Species differences in lifespan, organ structure, metabolism, telomere regulation and drug pharmacokinetics further limit direct extrapolation. The tumour spectrum after p53 loss, for example, is informative about tumour suppression but does not by itself reproduce the distribution of human TP53-mutant cancers.^[ref]

The endpoint and intervention must fit the biological question. Subcutaneous growth measures a local mass under an artificial geometry; tail-vein injection measures selected post-entry metastatic steps. Neither establishes a treatment effect on natural invasion or initial dissemination. Drug tests should establish exposure and target engagement in both tumour and relevant normal tissue, use clinically motivated schedules where possible, and measure survival or durable disease control as well as short-term volume. Rapidly growing implants may make some treatments look more effective than they are against slow, heterogeneous human disease.

Good design uses random allocation after a defined eligibility point, blinded measurement, prespecified endpoints and justified numbers of independent animals. Multiple tumours within one mouse are not automatically independent treatment replicates. Match or record relevant background variables and validate the intended allelic change and molecular phenotype. Ethical constraints favour well-chosen questions and informative longitudinal measurements rather than duplicating a weak model at larger scale. Combine mouse results with human genomics, patient-derived cultures or organoids and, ultimately, human evidence. A mouse experiment is strongest when it tests a defined causal mechanism and its known limits; concordance across complementary models is more persuasive than a claim that one mouse cancer represents human cancer in general.

Yes: a microRNA can suppress tumour formation or progression by restraining an oncogenic programme, but that role must be demonstrated for a defined microRNA, tissue and genetic context. Reduced expression in a tumour or growth inhibition after massive microRNA mimic transfection is suggestive rather than sufficient evidence of an endogenous tumour-suppressor function.

microRNAs are short regulatory RNAs whose guide strands associate with Argonaute. Recognition through sequence complementarity, often involving a microRNA seed region and a target's 3′ untranslated region, can recruit translational repression and RNA decay machinery. Canonical precursor processing involves Drosha and Dicer, although not every microRNA follows every canonical step. A microRNA can affect many transcripts, and a transcript can receive input from several microRNAs. Therefore modest coordinated repression of several growth or survival factors can have a substantial phenotype even without complete elimination of one target. Suppression is a property of the regulatory network, not of an RNA being universally “anticancer”.

The let-7 family supplies a mechanistic example. Experiments connecting let-7-responsive sequences in Ras transcripts with regulation of Ras expression linked a developmental regulatory RNA to a conserved growth pathway.^[ref] Reduced let-7 in lung cancer is compatible with loss of this restraint, but the inverse expression relationship alone would not show causation. Functional experiments restoring let-7 in relevant lung-cancer systems suppressed tumour development, providing a stronger test of tumour-suppressive capacity.^[ref] Expression should still be compared with a physiological range, and one must distinguish preventing tumour initiation from treating an established tumour.

Genetic loss gives a complementary direction of evidence. The miR-15a and miR-16-1 cluster lies within a recurrently deleted region associated with chronic lymphocytic leukaemia. Deletion of the corresponding mouse regulatory region or the microRNA cluster increased B-cell proliferative abnormalities and produced clonal lymphoproliferative disease in a subset of animals.^[ref] Comparing the smaller cluster deletion with a larger deletion matters because neighbouring genes can contribute to a human copy-number association. Disease after specific microRNA loss supports endogenous restraint more directly than an expression signature does; incomplete penetrance and latency imply cooperation and context rather than an automatic one-step conversion of every b cell.

The p53–miR-34 connection illustrates both strength and limitation of a proposed pathway. p53 activation can induce miR-34-family transcription, and ectopic miR-34 family can restrain proliferation or promote death in suitable biological cells, connecting a transcriptional tumour suppressor with post-transcriptional repression.^[ref] Yet mice lacking all three miR-34 family members retained substantial p53-dependent arrest and apoptosis and did not show the predicted general increase in tumour susceptibility in the tested settings.^[ref] This does not prove that miR-34 family cannot suppress a tumour in any setting. It shows that a gain-of-function phenotype and placement downstream of p53 do not establish that the microRNA family is an indispensable general mediator of p53 tumour suppression.

A convincing analysis combines several evidence types. Measure mature guide RNA in defined malignant and normal biological cell populations, distinguishing it from precursor abundance and changes in stromal composition. Determine whether deletion, promoter silencing or altered processing explains loss. Reduce or delete the endogenous microRNA and test initiation or progression in a suitable model, with restoration from a controlled expression system. Compare related family members to expose redundancy. Use seed-mutant controls and multiple reagents to distinguish sequence-specific regulation from delivery toxicity or innate immune activation; deleting an entire processing enzyme is not a specific test of one microRNA because it affects many regulatory RNAs.

To identify consequential targets, combine binding evidence, early RNA/protein responses and target-site tests. A 3′-region reporter whose seed-complementary site is mutated supports direct sequence-dependent regulation, but the decisive endogenous test is to edit the site or express a suitably controlled microRNA-resistant target and ask whether it rescues the phenotype. Failure of one target to rescue can reflect regulation of several cooperating targets rather than absence of specificity. Conversely, rescuing only bulk proliferation does not establish which target controls invasion or metastasis. Measure relevant tissue phenotypes and target protein levels, not merely a pathway enrichment score from predicted targets.

Tumour-suppressive activity also does not guarantee an effective therapy. Delivery must reach the relevant biological cells and release the RNA into the correct compartment without excessive exposure of normal tissues. A clinical miR-34a microRNA mimic study encountered serious immune-mediated toxicity, illustrating that an endogenous regulatory rationale does not establish safe systemic replacement.^[ref] Target abundance, isoform-specific 3′ regions and competing pathways can change the effect of the same microRNA between tumours. microRNAs can be genuine tumour suppressors; the strongest evidence is specific endogenous loss, controlled restoration and mechanistic target tests, interpreted alongside genetic redundancy and tissue context.

The large breakage frequencies occur mainly at supraphysiological NVNA1 levels; the probability at the mean latent level is not measured directly. At 20 ng/ml doxycycline, NVNA1 is already about twice the latent amount, and breakage is about 8%. At 50 ng/ml, the protein is approximately eightfold above latent levels and breakage about 25%; at 100 ng/ml, approximately sixteenfold and about 45–50%. Higher induction reaches roughly 60% while expression rises to about 21–24 times the latent level. The western blot loading control supports a protein-abundance comparison, although quantitative interpretation also requires unsaturated immunoblot detection.

Latent expression, defined as a ratio of one, lies below the lowest nonzero measured dose. Extrapolating a straight line from baseline and the twofold point would suggest a small frequency, but neither linearity nor a threshold is established. The justified conclusion is lower expected short-term breakage than in the strongly induced conditions, with a potentially important effect of modest upward fluctuations. Cell-to-cell variability, duration of expression and repeated divisions could make uncommon events consequential during a persistent infection. A percentage of broken chromosomes in this assay is not a patient's lifetime cancer probability. Doxycycline and tag controls are also needed to attribute the induced-cell phenotype specifically to NVNA1.

NVNA1 could contribute to cancer by increasing the chance of host chromosome damage and heritable rearrangements. Persistent occupancy of a chromosomal fragile site could obstruct replication or normal chromatin reassembly. Incompletely replicated or damaged DNA can break, mis-segregate and be repaired into deletions, gene fusions or copy-number alterations. Particular surviving rearrangements might remove a tumour suppressor gene or deregulate an oncogene, after which clonal selection could expand that lineage. A viral protein can therefore promote genomic instability without the viral genome having to integrate at every breakpoint.

The tumour-sequencing association is consistent with this mechanism but does not establish causality by itself. tumour type, pre-existing instability, infection detection sensitivity and cellular composition can confound an NV-positive/NV-negative comparison. The induction experiment strengthens the case that NVNA1 can damage the locus, while its high doses limit direct estimation of risk during ordinary viral latency. Very common infection is compatible with rare cancer because susceptible biological cell types, expression fluctuations, time and cooperating alterations all matter. A documented biological analogue links EBNA1 occupancy of a chromosome 11 repeat cluster to chromosome breakage and rearrangement.^[ref]

Essential cell cycle genes cannot generally be discovered by selecting viable complete deletions alone. A temperature-sensitive mutation solves this problem: its product supports growth under permissive conditions but fails under restrictive conditions. Screen conditional mutants for a reproducible division defect, then distinguish a specific cycle block from nonspecific loss of viability. A cdc mutant is defined by its cycle phenotype, not simply by poor growth at high temperature.

In Saccharomyces cerevisiae, bud size and nuclear morphology provide convenient stage markers. After shifting an asynchronous culture, mutants defective at a particular step tend to accumulate with a characteristic morphology. Leland H. Hartwell and colleagues used time-lapse observations to distinguish the time a function must act from the stage at which its absence becomes visible. Temperature-shift timing, DNA-content measurements and recovery after return to permissive conditions strengthen the interpretation. A delayed terminal phenotype need not identify the moment of the original molecular defect.^[ref]

In Schizosaccharomyces pombe, elongated cells that continue growing without dividing are especially useful candidates; nuclear number, septum formation and DNA content separate blocks in replication, mitosis and division. Paul Nurse, Pierre Thuriaux and Kim Nasmyth isolated conditional mutants defining multiple essential functions. Complementation testing groups recessive mutations affecting the same function, and segregation analysis distinguishes linked from independent loci. Molecular identification, rescue and biochemical tests then establish what the affected products do.^[ref]

Three contrasting examples explain why similar-looking division blocks need not have the same cause. In fission yeast, Cdc2, the cyclin-dependent kinase 1 catalytic subunit, is required for key cycle transitions. A restrictive loss-of-function allele can leave cells growing without entering mitosis; some alleles also reveal the earlier requirement at Start. Cdc25 is an activating protein phosphatase that removes inhibitory phosphorylation from Cdc2. Loss of Cdc25 therefore leaves the mitotic kinase inadequately activated and commonly produces an elongated G2-arrested phenotype. In budding yeast, Cdc6 participates in DNA replication licensing: failure to establish competent origins prevents successful genome duplication and hence normal division. Species and allele must be stated: identically numbered CDC names in different yeasts are not automatically homologous proteins.

The importance for cancer is that an unbiased genetic screen exposed conserved mechanisms connecting growth, DNA duplication and division. The yeast cross-species complementation experiment showed that central regulatory functions could be conserved across large evolutionary distances. Human cancers can alter cyclin-CDK regulation, DNA-replication control and checkpoint responses, providing a mechanistic connection to uncontrolled proliferation and genomic instability. This does not mean that every yeast cdc gene is a human oncogene, nor that any observed arrest is necessarily a checkpoint response: direct loss of an essential activity can itself stop progression.

Genomic instability means an elevated propensity to acquire genetic alterations. It includes changes in nucleotide sequence, repeat length, chromosome structure and chromosome number. A genome carrying one fixed alteration is not, by that fact alone, genomically unstable: instability concerns the process that generates further alterations.

At the sequence level, DNA replication introduces mismatches and small insertion-deletion errors. Polymerase proofreading and DNA mismatch repair normally suppress their fixation. Failure of mismatch repair is particularly evident as microsatellite instability. Damaged bases, stalled replication forks and collisions with transcription can increase replication stress; unrepaired or improperly repaired lesions can produce substitutions and rearrangements. Homologous recombination and non-homologous end joining solve different repair problems, and inappropriate use or incomplete repair can alter genome structure.

At the chromosome level, failed chromosome-end protection can allow end fusion. Subsequent separation of fused chromosomes can initiate breakage-fusion-bridge cycles, producing repeated rearrangement and copy-number change. Faulty kinetochore attachment, weakened sister chromatid cohesion or abnormal spindle organization can cause chromosome missegregation and aneuploidy. The resulting imbalances may themselves disturb cell physiology and DNA replication. DNA confined in an aberrant micronucleus can experience defective replication and fragmentation; repair of clustered fragments is one route to chromothripsis, rather than every rearrangement arising through that mechanism.^[ref]

The experimental signatures distinguish mechanisms. Mutation spectra and mismatch-repair status address sequence errors; repeat-length distributions address microsatellite instability; karyotyping, copy-number profiles and live chromosome imaging address numerical or structural chromosome instability. Single-cell or lineage-resolved measurements can show ongoing production of new states. A mixed endpoint population alone cannot establish whether variation arose rapidly during the experiment or was selected from pre-existing diversity.

In cancer, instability can generate selectable combinations that promote growth, escape from controls or resistance to treatment. It is neither automatically beneficial to the tumour nor sufficient for malignant transformation: excessive instability can impair proliferation or trigger apoptosis and cellular senescence. Examples of mechanistic connections include mismatch-repair deficiency in Lynch syndrome, homologous-recombination defects involving BRCA1 or BRCA2, and inherited replication or repair disorders. Chromosome missegregation can also contribute to developmental disease, pregnancy loss and infertility; instability in long-lived somatic tissues can impair function without producing a tumour.

A useful causal analysis asks what fails first, what alterations it produces, and which cellular responses restrain or select the affected cells. Restoring a repair factor or correcting a segregation defect should reduce the appropriate new-error rate, not merely change which clone grows best. The same reasoning explains why a genomic-instability phenotype can be informative in disease while remaining insufficient to diagnose a particular condition from morphology alone.

An organism contains genetic elements and cell lineages whose transmission interests need not coincide. Conflict arises when increasing an element's representation in descendants or within the body differs from maximizing the organism's reproductive success. Shared residence does not guarantee shared evolutionary interests, but neither does every difference between genes constitute conflict. A convincing account identifies the competing lineages, their transmission routes, and the outcomes favoured by selection on each.

Ordinary Mendelian segregation helps align the interests of unlinked nuclear loci: most depend on the same successful organism and receive an approximately equal chance of entering its gametes. intragenomic conflict becomes possible when an element bypasses that shared route, biases transmission, replicates within the genome, or has a parent-specific effect on relatives. mutation supplies variation; genetic linkage can protect combinations involved in distortion, while recombination and selection at other loci can favour suppression. The fitness currency of a selfish genetic element is therefore its own propagation, not the apparent health or fecundity of its carrier.

meiotic drive provides a direct example. For a rare autosomal driver with transmission probabilities $t_f$ through heterozygous females and $t_m$ through heterozygous males, suppose, for illustration, that heterozygotes have the same viability factor $1-s$ in both sexes. With random mating and otherwise equal reproductive contributions, the rare-driver approximation is:A rare driver can increase when the multiplier exceeds one, despite a carrier cost. This accounting also shows why the sex in which drive occurs matters: with unbiased male transmission, $t_m=1/2$, not $t_m=t_f$. The approximation omits dominance in common genotypes, sex-specific fertility, linkage and suppressors; it is an explanatory invasion calculation rather than a quantitative model of every natural driver.

Asymmetric female meiosis creates one route to distortion because some products become eggs and others are discarded. In monkeyflowers, a centromere-associated allele showed a strong female transmission advantage, with male fertility costs that expose a conflict between transmission and organismal performance. ^[ref] Reciprocal crosses and appropriate genetic backgrounds are important: distorted counts among surviving offspring can result from embryonic viability differences rather than biased segregation. Direct observation or genotyping of gametes and early embryos helps identify the stage. centromere drive is consequently more specific than merely observing segregation distortion.

The evolutionary response can include drive suppressors at other loci. Suppression is favoured when restoring fair transmission or reducing fertility costs improves the propagation of the rest of the genome. Its effect depends on linkage: a modifier tightly associated with the driver can experience different selection from an unlinked modifier. Arms races can maintain polymorphism and alter reproductive mechanisms; conversely, a successful suppressor can conceal an earlier conflict. Present-day Mendelian ratios therefore do not establish that transmission has always been conflict-free.

Transposable elements exploit another route: copying or moving genetic material within a lineage. McClintock's maize experiments established mobile controlling elements through genetic and cytological observations, providing foundational evidence that genomic components need not occupy fixed positions. ^[ref] Mobility itself is not proof that every element is harmful or selfish in every context. The conflict hypothesis requires a replication or transmission advantage alongside consequences for other genomic functions. Host silencing through mechanisms such as RNA interference and DNA methylation can constrain propagation, while some formerly mobile sequences acquire useful regulatory functions. Current usefulness and historical origin are different claims.

genomic imprinting illustrates conflict through expression rather than transmission distortion. Maternally and paternally inherited copies can differ in their relatedness to individuals affected by resource allocation. If a mother's future offspring are less likely to share the current father, a paternally inherited copy in the current offspring can place relatively less weight on those future maternal offspring. kinship theory of genomic imprinting therefore predicts disagreement over resource extraction under specified mating and life-history assumptions. It does not predict opposed interests at every locus or in every mating system. ^[ref]

Targeted disruption of the mouse insulin-like growth factor 2 gene produced growth effects dependent on parental transmission, demonstrating parent-of-origin-dependent regulation of an important growth factor. ^[ref] This is mechanistic evidence for imprinting. It is not, by itself, proof that parental genetic conflict caused the evolutionary origin of that regulatory pattern. Testing that explanation requires comparisons among related species and mating systems, tissue-specific expression, effects on maternal and offspring fitness, and alternatives such as dosage regulation or coadaptation. The genetic copy's interest must not be confused with a father's conscious preference or with a universal claim that larger offspring are always better for one parent.

The broader category also includes conflicts between distinct genomes residing in one individual. cytoplasmic inheritance can make an organelle or microbial symbiont depend mainly on female transmission, whereas nuclear loci are ordinarily transmitted through both sexes. A maternally inherited symbiont can consequently spread through changes to reproduction that do not benefit every host. In Nasonia wasps, reciprocal crossing, chromosome observations and antibiotic removal connected cytoplasmic microorganisms to reproductive incompatibility and abnormal paternal chromosome condensation. ^[ref] This demonstrates a microbial cause of a barrier under those conditions, not necessarily the origin of every species difference. Antibiotic effects on host condition and other microbes require controls, and reintroduction experiments would strengthen microbial specificity.

somatic evolution is a related conflict at a different level. A mutant cell lineage can increase within a body by avoiding growth restraint or cell death while damaging the organism. Analyses of cancer genomes and normal somatic tissues identified patterns of selection on somatic mutations, showing that cellular success is an evolutionary quantity distinct from organismal success. ^[ref] Not all cell proliferation is selfish, and some detected mutations are passengers. Mutation-rate heterogeneity, tissue composition and sequencing ascertainment must be modelled before an excess of mutations is interpreted as selection.

Such conflicts have consequences beyond immediate harm. They can favour fair-segregation mechanisms, genome defence, regulated cell proliferation and restrictions on which cell lineages produce offspring. A single-cell bottleneck and germ-soma separation can increase alignment among cellular descendants or limit transmission of within-body competitors, although neither prevents new mutations. Conflict can also affect fertility, sex ratios, reproductive isolation and genome organization. Claims that it produced a particular major evolutionary change require historical and comparative evidence in addition to a plausible selective argument.

Organismal integration is partly an evolved outcome of controlling conflict, not evidence that conflict is absent. The strongest explanations connect a specific transmission asymmetry to an element's advantage, a measurable cost or opposed interest, and an experimentally or comparatively supported response.

Conflicts are reduced by changing who benefits from cooperation, constraining opportunities for selfish success, or imposing costs on exploiters. The same logic operates between organisms and inside them, but the units that reproduce and transmit differ. Resolution need not mean eliminating all conflict or giving every participant its preferred outcome: it can be a stable compromise, suppression by a powerful party, or a continuing arms race.

An evolutionary conflict exists when different inherited strategies or replicating lineages favour different outcomes. Between organisms, individuals may disagree over resources, mating or contributions to a shared activity. Within an organism, cell lineages can gain from proliferating at their neighbours' expense, and genes can gain a transmission advantage that harms the rest of the genome. A common environment or membership of one body does not guarantee identical interests.

Between organisms, alignment can make restraint individually worthwhile. Genetic relatedness can reward benefits to relatives through inclusive fitness; repeated interaction can link current help to later returns; and partner choice can make productive cooperation a condition of continued association. Reliable exchange can also make a partner's survival directly valuable. None of these mechanisms requires conscious agreement. They work only where their gains outweigh the available selfish alternative, including the costs of assessment and enforcement.

Conditional allocation supplies another route. In soybean experiments, preventing rhizobial nitrogen fixation reduced bacterial reproductive success, while physiological measurements implicated reduced oxygen supply to non-fixing nodules. This supports host control that makes poor service costly to the symbiont. The treatment forced noncooperation in an otherwise cooperative strain: it tests the consequences of service failure, rather than demonstrating the evolutionary origin of a particular cheating mutation.^[ref]

Social insects show how relatedness and enforcement interact without making a colony conflict free. Workers can produce haploid sons, creating disagreement over male production. With a sufficiently multiply mated queen, a worker may be more related to queen-produced males than to the average other worker's sons. Experiments in honeybees found strong discrimination against worker-laid male eggs, supporting worker policing. The result establishes differential treatment of eggs; relatedness and colony productivity are possible selective benefits and must be evaluated rather than assumed equivalent.^[ref]

Within multicellular organisms, common descent changes the baseline. Development from a single-cell bottleneck normally makes most cells close genetic relatives and links their lineage's long-term transmission to successful reproduction of the organism. Germline-soma differentiation further restricts the routes by which a proliferating somatic lineage can reach future generations. These features help explain extensive cellular cooperation, but they are incomplete protection: somatic mutation can create a clone that grows faster within the body even while lowering host survival or reproduction.

Cell-cycle regulation, DNA-damage responses, apoptosis, tissue architecture and immune responses can restrict such expansion. Some mechanisms remove damaged cells; others reduce opportunities for spread or prevent extra divisions from translating into transmission. Their developmental and maintenance functions mean that they should not all be described as adaptations exclusively for cancer suppression. Cancer demonstrates that the constraints can fail, especially when selection on the organism is weak at ages after most reproduction.

Apoptosis and cell competition are also not automatically measures of collective welfare. In experimental Drosophila tissues, higher Myc expression made clones eliminate lower-Myc neighbours and expand at their expense. This showed that a process involving elimination of neighbouring cells can be exploited by a locally successful lineage. It cautions against labelling whichever cells win a contest “best for the organism.”^[ref]

Genetic conflict can persist even when cells descend from one zygote, because loci may have different transmission rules. A sex-linked meiotic driver can increase its own representation by impairing gametes carrying the alternative chromosome. Autosomal alleles can instead favour restoration of a more balanced transmission system. In Drosophila simulans, genetic and molecular work identified the autosomal suppressor not much yang, which suppresses an X-linked sex-ratio distorter; cytological work connected distortion to failure of Y-bearing sperm maturation. This is a concrete case of a genomic countermeasure, rather than an assumption that Mendelian inheritance is intrinsically immune to selfish elements.^[ref]

The comparison reveals two common principles. First, common transmission can align interests, as in relatives, vertically transmitted symbionts and clonally developing cells. Second, discrimination can make selfish strategies less profitable, as in partner sanctions, worker egg removal and suppression of a driver. Compartmentalization can help target the responsible partner or lineage, but its effect depends on scale: a compartment founded by one symbiont may reduce within-compartment mixing while still allowing competition among host compartments.

There are also important differences. Separate organisms can often leave, switch partners or use outside resources, so the costs of exit shape bargaining and partner choice. An ordinary somatic cell has few such reproductive alternatives and is usually integrated into a developmentally specified body. Genes inside that cell cannot choose partners in the behavioural sense, but recombination, linkage and differential transmission change the selection acting on suppressors. At either scale, suppression can select for evasion, producing continuing counteradaptation rather than permanent harmony.

A successful explanation therefore specifies the competing units, their routes of transmission, the benefit of the proposed control mechanism, and the level at which success is measured. More offspring, more surviving symbionts, a larger clone and greater representation of one chromosome are different outcomes. Conflicts are resolved to the extent that mechanisms make the lower-level selfish alternative less successful relative to its competitors; neither organismal organization nor social cooperation is evidence that the underlying conflict has vanished.

British Journal of cancer 122, 1630–1637 (2020). Publisher record. Primary article or institutional bibliographic record.

cancer biological cell 17, 28–40 (2010). Publisher record. Primary article or institutional bibliographic record.